E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Large (>/=3 cm) or locally advanced breast cancers |
|
E.1.1.1 | Medical condition in easily understood language |
Breast cancer confined to the breast and draining lymph glands. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057654 |
E.1.2 | Term | Breast cancer female |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate whether capecitabine, when combined with docetaxel and following adriamycin and cyclophosphamide, can significantly enhance the complete pathological response rate (> 30%) in the primary breast cancers and tumour draining axillary lymph nodes of women with large or locally advanced breast cancers (LLABCs). |
|
E.2.2 | Secondary objectives of the trial |
2.2.1 To document the quality of life (QoL) and related morbidity with these novel drug combinations, including the use of G-CSF in a primary prophylactic setting.
2.2.2 To define, accurately and reliably, the predictive value of response to chemotherapy of specific proteins/genes, previously identified and characterised in an in vitro study.
2.2.3 To evaluate the host defences in women with breast cancer undergoing chemotherapy, and establishing the contribution of these defences to the beneficial effects documented.
2.2.4 To assess the effectiveness of magnetic resonance mammography scans as predictors of early clinical response to neoadjuvant chemotherapy.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Women with histologically confirmed carcinoma of the breast, with measurable or evaluable large (≥ 3cm) or locally advanced (T3, T4, TxN2) disease
2. Women who are over 18 and under 75 years and able to sign the informed consent
3. Ability to comply with study and follow-up procedures
4. Adequate left ventricular function at study entry, defined as LVEF ≥ 50% by echocardiography (ECHO)
|
|
E.4 | Principal exclusion criteria |
1. WHO performance status 2, 3 and 4
2. Prior chemotherapy or radiotherapy unless for basal cell carcinoma
3. Unstable angina and/or evidence of significant cardiac dysfunction
4. Patients who have diabetes requiring insulin
5. Pregnancy or lactation
6. Inadequate organ function, as evidenced by any of the following laboratory values: Absolute neutrophil count < 1500/uL; Platelet count < 100,000/uL; Total bilirubin > 1.5 mg/dL; Alkaline phosphatase, AST, and/or ALT > 2x upper limit of normal; Serum creatinine > 2.0 mg/dL; PTT and/or either INR or PT > 1.5x upper limit of normal (except for subjects receiving anti-coagulation therapy); Urine protein/creatinine ratio > 1.0 at screening
7. Inability to complete Quality of Life questionnaires
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To improve the complete pathological response rate of the breast cancer and tumour draining axillary lymph nodes to a novel combination of drugs in the neoadjuvant setting. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Following completion of trial. |
|
E.5.2 | Secondary end point(s) |
To document the quality of life (QoL) and related morbidity with these novel drug combinations, including the use of G-CSF in a primary prophylactic setting.
To define, accurately and reliably, the predictive value of response to chemotherapy of specific proteins/genes, previously identified and characterised in an in vitro study.
To evaluate the host defences in women with breast cancer undergoing chemotherapy, and establishing the contribution of these defences to the beneficial effects documented.
To assess the effectiveness of magnetic resonance mammography scans as predictors of early clinical response to neoadjuvant chemotherapy.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
To document the quality of life (QoL) and related morbidity with these novel drug combinations, including the use of G-CSF in a primary prophylactic setting: following completion of trial
To define, accurately and reliably, the predictive value of response to chemotherapy of specific proteins/genes, previously identified and characterised in an in vitro study: 18 months - 24 months after completion of trial.
To evaluate the host defences in women with breast cancer undergoing chemotherapy, and establishing the contribution of these defences to the beneficial effects documented: following completion of trial.
To assess the effectiveness of magnetic resonance mammography scans as predictors of early clinical response to neoadjuvant chemotherapy: following completion of trial.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Quality of life, host defences, imaging responses and proteomic predictors |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Stratification according to image response: followed by randomisation of responders/non responders |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |